



INTERIM REPORT

January to June 2020



GROUP KEY FIGURES

		Q2 2020	Q2 2019	H1 2020	H1 2019
Income statement					
Sales revenue	EUR thousand	4,927	4,983	9,600	9,768
Gross profit	EUR thousand	2,979	3,126	5,749	6,015
EBITDA	EUR thousand	1,442	1,497	2,607	2,789
EBITDA margin on sales	%	29.3	30.0	27.2	28.6
Operating result (EBIT)	EUR thousand	833	883	1,388	1,560
Result for the period	EUR thousand	741	586	1,109	1,048
Earnings per share	EUR	0.18	0.14	0.27	0.26
Balance sheet				06/30/2020	12/31/2019
Balance sheet total	EUR thousand			61,216	61,099
Equity	EUR thousand			31,388	30,268
Equity ratio	%			51.3	49.5
Liquid funds	EUR thousand			9,938	9,102
Cash flow				H1 2020	H1 2019
Investments	EUR thousand			283	413
Depreciation and amortization	EUR thousand			1,218	1,229
Cash flow from operating activities	EUR thousand			1,842	2,359
Employees				06/30/2020	12/31/2019
On the balance sheet date	Number			120	120

CONTENT

2 To our Shareholders

- 2 Letter from the Management Board
- 4 Vita 34 AG Shares

5 Interim Group Management Report

- 5 Business Report
- 6 Opportunity and Risk Report
- 6 Forecast Report

7 Condensed Interim Consolidated Financial Statements

- 7 Condensed Consolidated Income Statement
- 8 Condensed Consolidated Statement of Comprehensive Income
- 9 Condensed Consolidated Balance Sheet (Assets)
- 10 Consolidated Balance Sheet (Equity and Liabilities)
- 11 Condensed Consolidated Statement of Changes in Equity
- 13 Condensed Consolidated Cash Flow Statement
- 14 Notes to the Condensed Interim Consolidated Financial Statements

17 Responsibility Statement

18 Financial Calendar

18 Imprint

LETTER FROM THE MANAGEMENT BOARD

Dear Shareholders,

With an EBITDA margin of 29.3%, we were able to achieve an extraordinarily good result in the second quarter of 2020. A solid first quarter with an EBITDA of EUR 1.2 million, which was mainly characterized by an intensification of marketing and sales expenses, was exceeded by 23.9% in the second quarter with an EBITDA of EUR 1.4 million. The profitability thus achieved in the first six months of 2020 is very satisfactory considering the general economic environment and meets our expectations. Compared to the previous year, we still have to record a slight reduction in the first half of the year, but we are still on a par with the previous year in terms of sales and EBITDA, particularly in the second quarter.

At EUR 9.6 million, sales in the first half of the year are still slightly below the previous year's level (EUR 9.8 million). In the detailed analysis, however, it becomes apparent that sales in the second quarter have already increased again by 5.4% compared to the previous quarter. We are currently seeing this recovery effect in incoming orders beyond the second quarter, which also makes us optimistic about the further business development.

The development of sales and profitability shows that the COVID-19 pandemic is currently having only a moderate impact overall on our business development. In the DACH market, the temporary restrictions on the travel activities of our sales representatives meant that we were unable to establish personal contact with customers, gynecologists and midwives to the extent we had hoped. The web-based communication tools we have established have had a stabilizing effect, but do not replace personal contact in the long term. However, the situation here has also improved again, especially in our core market DACH.

Accordingly, we can confirm our full-year forecast for 2020. We continue to expect EBITDA of between EUR 4.8 and 5.8 million. Without acquisitions, sales should reach a value between EUR 19.0 and 21.0 million.

Our earnings figures for the first half of the year already include one-off increases in legal and consulting fees incurred in the course of the takeover offer. Our actual operating earnings power is therefore actually slightly higher than we reported. For you, dear shareholders, the progress of the takeover offer was of course also of interest. We published our reasoned statement on our website on July 3, 2020. After their respective independent and autonomous examination of the offer document and the circumstances accompanying the offer, the Management Board and the Supervisory Board did not consider the amount of the offer price to be appropriate within the meaning of section 31 para. 1 WpÜG. The mandatory offer was accepted for 217,510 Vita 34 shares by the reporting date. This corresponds to a share of 5.25% of the share capital and voting rights of Vita 34 AG. According to its last voting rights announcement on August 5, 2020, AOC Health GmbH thus holds a total share of 36.44%.

At the Annual General Meeting on July 1, 2020, Mr. Florian Schuhbauer was elected to the Supervisory Board of Vita 34 AG. The Management Board warmly welcomes Mr. Florian Schuhbauer as a new member of the Supervisory Board of Vita 34 AG. We look forward to a good and trusting cooperation with him and our new major shareholder, AOC Health GmbH. In the constituent meeting on July 2, 2020, the Supervisory Board elected Mr. Florian Schuhbauer as Chairman of the Supervisory Board.

For the further development of the company, we continue to focus on the targeted expansion of our business model. The starting points are manifold, in particular we will in future focus on the storage of stem cells from the body's autologous fat as well as immune cells from peripheral blood. Based on our conviction that the body's autologous cells will increasingly become a valuable source material for individual medical therapies in the future, we see great development potential for Vita 34. Together, we want to leverage this additional potential for Vita 34 and for the people whom medical progress in personalized medicine can specifically help.

Leipzig, August 26, 2020
The Management Board of Vita 34 AG



Dr. Wolfgang Knirsch
Chief Executive Officer



Falk Neukirch
Chief Financial Officer

Vita 34 AG Shares

Key share data H1 2020

Ticker symbol/Reuters symbol	V3V/V3VGn.DE
Securities identification number/ISIN	A0BL84/DE000A0BL849
Number of shares	4,145,959
Price on 01/02/2020*	EUR 12.95
Price on 06/30/2020*	EUR 12.95
Market capitalization on 06/30/2020*	EUR 53.7 million

* Closing prices Xetra trading system of Deutsche Börse AG


RESEARCH

In the first half of 2020, Vita 34 AG continued to be covered by the analysts of Montega AG and Warburg Research. In their current studies within the first six months of 2020, Montega AG and Warburg Research rated the Vita 34 share as “buy” with a price target of EUR 16.00 and EUR 15.00 respectively.

ANNUAL GENERAL MEETING

This year’s Annual General Meeting took place in virtual form for the first time on July 1, 2020. The shareholders approved all agenda items with a large majority.

Shareholder structure as of August 4, 2020



* Thereof, 36.44% are attributed to Mr. Florian Schuhbauer (32.56% AOC Health GmbH + 3.87% PBKM).

Share price development H1 2020 Indexed: 100 = Xetra closing price on January 2, 2020

— Vita 34 AG (indexed) — DAXsector Pharma & Healthcare (Perf.) (indexed) — NASDAQ HealthCare (indexed)



INTERIM GROUP MANAGEMENT REPORT

Business Report

DIRECT EFFECTS OF THE COVID-19 PANDEMIC ON THE RESULTS OF OPERATIONS, FINANCIAL POSITION AND NET ASSETS

The COVID-19 pandemic had hardly any direct impact on the course of business as well as on the results of operations, financial position and net assets of the Vita 34 Group in the first half of 2020. The company also did not make use of any assistance measures such as short-time work or government assistance loans. There were minor effects on general operating procedures, for example, due to the security measures implemented, the temporary absence of travelling by the field sales force and a slightly higher stockpiling of individual input materials. These effects are difficult to show separately in the results of operations, financial position and net assets and were only of minor significance overall.

TAKEOVER OFFER OF AOC HEALTH GMBH

AOC Health GmbH has submitted a takeover offer to the shareholders of Vita 34 AG and published the corresponding offer document on the Internet on June 29, 2020. On July 3, 2020, the Management Board and the Supervisory Board published a joint reasoned statement pursuant to section 27 WpÜG on the mandatory offer of AOC Health GmbH. By the reporting date, the mandatory offer was accepted for 217,510 Vita 34 shares. This corresponds to 5.25% of the share capital and voting rights of Vita 34 AG. According to its last voting rights announcement on August 5, 2020, AOC Health GmbH thus holds a total share of 36.44%.

RESULTS OF OPERATIONS

FIRST HALF OF 2020

In the first six months of 2020, sales revenues of EUR 9,600 thousand were generated, which is approximately the same level as the previous year's EUR 9,768 thousand. After a still somewhat restrained start into 2020, Vita 34 was able to gain significant momentum, particularly in the course of the second quarter. Overall, the core market DACH proved stable with an overall improving performance during the reporting period.

The gross profit weakened in the first half of the year from EUR 6,015 thousand to EUR 5,749 thousand. The reasons were slightly higher cost of sales due to a slight increase in the number of employees as well as a rise in consulting costs compared to the same period of the previous year. Accordingly, the gross margin (based on revenues) fell slightly from 61.6% to 59.9%.

The development of earnings before interest, taxes, depreciation and amortization (EBITDA) shows that the ongoing, still very high cost discipline based on the cost efficiency measures implemented in 2019 is taking effect. It did fall slightly in absolute figures from EUR 2,798 thousand to EUR 2,607 thousand. However, the EBITDA margin of 27.2% was almost confirmed at the very high level of the previous year (28.6%) and increased significantly again, particularly in the second quarter of 2020.

Marketing and selling expenses increased slightly in the reporting period. Vita 34 had already begun to intensify its marketing and sales activities in a focused manner in the fourth quarter of 2019 and continued to do so in the first half of 2020. Accordingly, marketing and selling expenses increased by 1.7%. Administrative expenses fell again compared to the prior-year period (-10.3%).

The operating result (EBIT) for the first half of 2020 was EUR 1,388 thousand compared to EUR 1,560 thousand in the same period of the previous year.

The changed tax assessment for a previous year resulted in tax income, which reduced the tax burden of the reporting period on a one-off basis compared to the previous year. After EUR 1,048 thousand in the same period of the previous year, a result for the period of EUR 1,109 thousand was achieved in the first half of 2020. Earnings per share are calculated accordingly at EUR 0.27 (H1 2019: EUR 0.26).

SECOND QUARTER OF 2020

The second quarter showed a noticeable improvement in sales momentum compared with the first quarter. Thus, the sales of the first quarter were exceeded by 5.4% and with EUR 4,927 thousand the level of the previous year's quarter was reached (Q2 2019: EUR 4,983 thousand).

Despite a slightly lower gross profit margin of 61% (Q2 2019: 63%), EBITDA of EUR 1,442 thousand was maintained at the level of the prior-year quarter (Q2 2019: EUR 1,497 thousand) and thus an EBITDA margin of 29.3% (Q2 2019: 30.0%) was achieved. Further savings in administrative costs were decisive here. Other operating expenses of EUR 150 thousand in the second quarter already include significant consulting costs in connection with the takeover offer by AOC Health GmbH. EBIT reached EUR 833 thousand after EUR 883 thousand in the previous year. At EUR 741 thousand, the result for the period was above the level of the previous year (Q2 2019: EUR 586 thousand), influenced by the reported one-off tax effect.

FINANCIAL POSITION

Due to the good earnings development, Vita 34 was able to generate a cash flow from operating activities in the first half of 2020 of EUR 1,842 thousand, which was slightly below the previous year's value of EUR 2,359 thousand, but still underlines the high internal financing power of the company. Decisive factors for the small decline were the slightly higher stockpiling for precautionary reasons in the course of the COVID-19 pandemic, moderately increased receivables as well as higher income tax payments. The cash flow from investing activities amounted to EUR –385 thousand in the same period of the previous year, whereas in the past half-year, a cash inflow was generated by the sale of financial investments, which resulted in a cash inflow of EUR 92 thousand netted with investments in property, plant and equipment. The cash flow from financing activities of EUR –1,098 thousand (H1 2019: EUR –1,638 thousand) consists primarily of planned repayments (EUR –820 thousand) and lease payments (EUR –277 thousand). The difference compared to the previous year's period results from the resolution of the Annual General Meeting to retain the profit for 2019 in full and, in contrast to 2019, to waive a dividend.

In total, the planned repayment of financial loans in the reporting period was offset by a waiver of the dividend payment as well as a significant operating cash flow and a one-off effect from the sale of financial investments, so that cash and cash equivalents as of June 30, 2020 increased to EUR 9,938 thousand (December 31, 2019: EUR 9,102 thousand).

NET ASSETS

The balance sheet total remained stable at EUR 61,216 thousand compared with the figure of EUR 61,099 thousand as of December 31, 2019. On the assets side of the balance sheet, non-current assets including goodwill decreased from EUR 48,221 thousand to EUR 47,178 thousand. The reason for this is the scheduled amortization of intangible assets resulting from the valuation of customer contracts in the course of acquisitions. Goodwill remained unchanged at EUR 18,323 thousand as of June 30, 2020.

Current assets increased to EUR 14,038 thousand as of the reporting date (December 31, 2019: EUR 12,878 thousand). The rise is composed of slightly higher inventories, refund claims for income taxes and, in particular, increased cash and cash equivalents. The total trade receivables are almost constant.

On the equity and liabilities side of the balance sheet, equity increased from EUR 30,268 thousand to EUR 31,388 thousand due to the positive half-year result. The equity ratio improved from 49.5% to 51.3%.

Non-current liabilities decreased to EUR 21,691 thousand as of June 30, 2020 (December 31, 2019: EUR 22,414 thousand). The lower interest-bearing loans of EUR 3,048 thousand (December 31, 2019: EUR 3,799 thousand) were offset by slightly increased deferred income taxes (EUR +263 thousand). Current liabilities fell to EUR 8,138 thousand (December 31, 2019: EUR 8,417 thousand).

Opportunity and Risk Report

A detailed opportunity and risk report is contained in the Annual Report 2019 (page 28 et seq.). There were no material changes in the reporting period compared with the opportunities and risks described therein.

Forecast Report

Against the background of the stable business development in the first half of 2020 and the indications for the further course of business to date, the Management Board of Vita 34 AG continues to maintain its forecast for the full year 2020. Sales revenues of between EUR 19.0 and 21.0 million (without acquisitions) and EBITDA of between EUR 4.8 and 5.8 million are expected.

The Management Board continues to assess the sensitivity of the Vita 34 business model to economic fluctuations as low. Based on experience to date, the COVID-19 pandemic is also not expected to have any far-reaching effects on business development. Accordingly, the effects of a possible significant further spread of COVID-19 are not taken into account.

FORWARD-LOOKING STATEMENTS

This report contains forward-looking statements. They are based on the current information available to Vita 34 at the time of the preparation of this report. However, such forward-looking statements are subject to risks and uncertainties. Should the underlying assumptions not materialize or should further opportunities/risks arise, the actual results may differ from the estimates made. Therefore, Vita 34 cannot assume any responsibility for this information.

Leipzig, August 26, 2020
The Management Board of Vita 34 AG



Dr. Wolfgang Knirsch
Chief Executive Officer



Falk Neukirch
Chief Financial Officer

CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

Condensed Consolidated Income Statement

EUR thousand	Q2 2020	Q2 2019	H1 2020	H1 2019
Sales revenues	4,927	4,983	9,600	9,768
Cost of sales	-1,948	-1,857	-3,851	-3,753
Gross profit on sales	2,979	3,126	5,749	6,015
Other operating income	107	126	334	276
Marketing and selling costs	-1,078	-1,156	-2,478	-2,438
Administrative expenses	-1,025	-1,201	-2,039	-2,273
Other operating expenses	-150	-12	-178	-20
Operating result (EBIT)	833	883	1,388	1,560
Financial income	46	22	51	26
Financial expenses	-46	-53	-96	-111
Earnings before taxes	832	852	1,344	1,475
Income tax expense	-91	-265	-234	-427
Result for the period after taxes	741	586	1,109	1,048
Attribution of the result for the period to				
Owners of the parent company	741	586	1,105	1,050
Non-controlling interests	0	0	4	-2
Earnings per share, undiluted/diluted (EUR)				
Undiluted and diluted, relating to the result for the period attributable to the holders of ordinary shares of the parent company	0.18	0.14	0.27	0.26

Condensed Consolidated Statement of Comprehensive Income

EUR thousand	Q2 2020	Q2 2019	H1 2020	H1 2019
Result for the period	741	586	1,109	1,048
Other comprehensive income				
Currency translation differences	8	0	10	1
Other comprehensive income to be reclassified to the income statement in subsequent periods	8	0	10	1
Other comprehensive income not to be reclassified to the income statement in subsequent periods	0	0	0	0
Total comprehensive income after taxes	748	587	1,119	1,049
Attribution of the comprehensive income after taxes to				
Owners of the parent company	748	587	1,115	1,051
Non-controlling interests	0	0	4	-2

Condensed Consolidated Balance Sheet (Assets)

EUR thousand	06/30/2020	12/31/2019
Non-current assets		
Goodwill	18,323	18,323
Intangible assets	17,818	18,525
Property, plant and equipment	7,331	7,285
Right-of-use assets	1,663	1,905
Other assets	1,003	1,012
Trade receivables	921	632
Restricted cash	119	540
	47,178	48,221
Current assets		
Inventories	396	294
Trade receivables	2,753	2,879
Income tax receivables	198	44
Other receivables and assets	752	559
Cash and cash equivalents	9,938	9,102
	14,038	12,878
Total Assets	61,216	61,099

Consolidated Balance Sheet (Equity and Liabilities)

EUR thousand	06/30/2020	12/31/2019
Equity		
Subscribed capital	4,146	4,146
Capital reserves	24,012	24,012
Retained earnings	3,545	2,440
Other reserves	-173	-183
Treasury shares	-261	-261
Non-controlling interests	118	114
	31,338	30,268
Non-current liabilities		
Interest-bearing loans	3,048	3,799
Lease liabilities	1,133	1,356
Deferred grants	772	797
Contract liabilities	11,576	11,563
Provisions	14	14
Pension provisions	56	56
Deferred income taxes	5,091	4,828
	21,691	22,414
Current liabilities		
Trade payables	1,351	1,266
Provisions	75	104
Income tax liabilities	462	703
Interest-bearing loans	1,534	1,584
Lease liabilities	535	546
Deferred grants	47	45
Contract liabilities	2,775	2,871
Other liabilities	1,359	1,298
	8,138	8,417
Total Equity and Liabilities	61,216	61,099

Condensed Consolidated Statement of Changes in Equity

Equity attributable to the owners of the parent company				
EUR thousand	Subscribed capital	Capital reserves	Retained earnings	Reserve for financial assets available for sale
As of January 1, 2019	4,146	23,913	1,848	-26
Result for the period	0	0	1,050	0
Other income	0	0	0	0
Total income	0	0	1,050	0
Dividend payments	0	0	-656	0
As of June 30, 2019	4,146	23,913	2,243	-26
As of January 1, 2020	4,146	24,012	2,440	-24
Result for the period	0	0	1,105	0
Other income	0	0	0	0
Total income	0	0	1,105	0
As of June 30, 2020	4,146	24,012	3,545	-24

Equity attributable to the owners of the parent company						
Revaluation reserves	Currency translation differences	Total equity	Treasury shares at acquisition cost	Non-controlling interests	Total equity	
-122	3	29,762	-337	122	29,546	
0	0	1,050	0	-2	1,048	
0	1	1	0	0	1	
0	1	1,051	0	-2	1,049	
0	0	-656	0	0	-656	
-122	4	30,157	-337	119	29,939	
-160	1	30,415	-261	114	30,268	
0	0	1,105	0	4	1,109	
0	10	10	0	0	10	
0	10	1,115	0	4	1,119	
-160	11	31,530	-261	118	31,388	

Condensed Consolidated Cash Flow Statement

EUR thousand	H1 2020	H1 2019
Cash flow from operating activities		
Result for the period before income taxes	1,344	1,475
Adjustments for:		
Depreciation and amortization	1,218	1,229
Gains/losses from the disposal of non-current assets	4	0
Other non-cash expenses/income	2	-38
Financial income	-51	-26
Financial expenses	96	93
Changes in net working capital:		
+/- Inventories	-102	89
+/- Receivables and other assets	-254	-1
+/- Liabilities	145	-260
+/- Contract liabilities	-84	82
+/- Provisions	-29	-21
Interest paid	-79	-85
Income taxes paid	-369	-178
Cash flow from operating activities	1,842	2,359
Cash flow from investing activities		
Purchase of intangible assets	-19	-7
Purchase of property, plant and equipment	-264	-407
Proceeds from the sale of property, plant and equipment	0	2
Proceeds from the sale of financial investments	370	0
Interest received	5	26
Cash flow from investing activities	92	-385
Cash flow from financing activities		
Proceeds from the issue of shares	0	176
Dividend payments	0	-656
Payments for the repayment of financial loans	-820	-891
Payments for leases	-277	-267
Cash flow from financing activities	-1,098	-1,638
Net change in cash and cash equivalents	836	336
Cash and cash equivalents at the beginning of the reporting period	9,102	6,960
Cash and cash equivalents at the end of the reporting period (liquid funds)	9,938	7,297

Notes to the Condensed Interim Consolidated Financial Statements

1. INFORMATION ON THE COMPANY

The unaudited condensed interim consolidated financial statements of Vita 34 AG include Vita 34 AG and its subsidiaries (together referred to as “Vita 34” or “Group”).

The parent company Vita 34 AG (the “company”), based in Leipzig (Germany), Deutscher Platz 5a, registered in the register court of the local court of Leipzig under HRB 20339, is a company whose corporate purpose is the collection, processing and storage of stem cells from umbilical cord blood and tissue, the development of cell therapeutic procedures as well as the implementation of projects in the field of biotechnology.

The interim consolidated financial statements for the period from January 1 to June 30, 2020 were approved for publication by the Management Board on August 26, 2020.

2. ACCOUNTING AND VALUATION PRINCIPLES

2.1. BASIS OF PREPARATION OF THE FINANCIAL STATEMENTS

The condensed interim consolidated financial statements for the period from January 1 to June 30, 2020 have been prepared in accordance with IAS 34 “Interim Financial Reporting”.

The condensed interim consolidated financial statements do not include all the explanations and disclosures prescribed for the annual financial statements and should be read in conjunction with the consolidated financial statements as of December 31, 2019.

2.2. FIRST-TIME APPLICATION OF NEW STANDARDS

The accounting and valuation methods applied in the preparation of the condensed interim consolidated financial statements correspond in principle to the methods applied in the preparation of the consolidated financial statements for the financial year as of December 31, 2019, with the exception of the amendments or new IFRS regulations that have been mandatory since January 1, 2020.

3. SALES REVENUES FROM CONTRACTS WITH CUSTOMERS

The sales revenues reported in the income statement for continuing operations are broken down by type of service provided as follows:

EUR thousand	H1 2020	H1 2019
Revenue processing/production	6,911	7,152
Revenue from storage	2,677	2,603
Other revenue	12	13
	9,600	9,768

4. OTHER OPERATING EXPENSES

Other operating expenses include expenses for consulting services in connection with the mandatory offer submitted by AOC Health GmbH to acquire all shares of Vita 34 AG in the amount of EUR 115 thousand.

5. INCOME TAXES

The Group calculates the periodic income tax expense at the tax rate that would have to be applied to the expected total annual result. The income tax expense is composed as follows:

EUR thousand	H1 2020	H1 2019
Actual income tax expense	-135	-210
Actual income tax income for previous years	162	0
Deferred income tax expense	-262	-217
	-234	-427

The tax authorities granted an existing appeal against the tax assessment of a Group company for a previous year. This resulted in a repayment claim for taxes paid in excess in previous years in the amount of EUR 159 thousand.

The increase in deferred income tax expenses results from the use of tax losses carried forward at Group companies.

The cash outflows for income taxes in the first half of 2020 amount to EUR 369 thousand (H1 2019: EUR 178 thousand) and result primarily from the tax assessment of a subsidiary for the financial year 2018.

6. FINANCIAL ASSETS AND FINANCIAL LIABILITIES

The carrying amounts of financial assets and financial liabilities are presented in the following tables. The carrying amount corresponds to the fair value.

EUR thousand	06/30/2020	12/31/2019
Financial assets		
Financial assets at amortized cost		
Trade receivables	3,674	3,511
Other financial assets	151	116
	3,825	3,628
Financial assets at fair value through other comprehensive income (FVtOCI)		
Securities investments	100	100
Other financial assets	233	233
	332	332
Total financial assets	4,157	3,960
Financial liabilities		
Financial liabilities at amortized cost		
Interest-bearing loans	4,583	5,383
Lease liabilities	1,668	1,902
Trade payables	1,351	1,266
Other financial liabilities	58	76
	7,659	8,627
Total financial liabilities	7,659	8,627

Current trade receivables, other financial receivables, trade payables and other financial liabilities regularly have short residual terms; the recognized values approximate the fair values.

The fair values of non-current trade receivables with residual terms of more than one year correspond to the present values of the payments associated with the assets, using a standard market interest rate. The classification was made in level 2 of the fair value hierarchy.

The fair value of securities investments is determined on the basis of stock exchange prices in active markets. The classification was made in level 1 of the fair value hierarchy.

The fair values of long-term loans and lease liabilities measured in the balance sheet at amortized cost were determined by discounting the expected future cash flows using standard market interest rates. In each case, the classification was made in level 2 of the fair value hierarchy.

The fair value of other financial assets is determined on the basis of suitable valuation methods. In each case, the classification was made in level 3 of the fair value hierarchy.

7. INFORMATION ON RELATIONS WITH RELATED COMPANIES AND PERSONS

Related companies and persons are subsidiaries not included in the consolidated financial statements, associated companies (and their subsidiaries), shareholders with significant influence and persons in key positions of the company.

The following tables contain significant transactions with related companies and persons for the period from January 1 to June 30, 2020 and 2019, respectively

EUR thousand	Revenues and earnings		Receivables	
	H1 2020	H1 2019	June 30, 2020	December 31, 2019
Non-consolidated subsidiaries	16	39	2	9

The Group maintains relations with non-consolidated subsidiaries in the course of its ordinary business activities. The Group generally sells services at market conditions.

8. EVENTS AFTER THE BALANCE SHEET DATE

After the reporting date of June 30, 2020, no reportable events have occurred.

Leipzig, August 26, 2020
The Management Board of Vita 34 AG

Dr. Wolfgang Knirsch
Chief Executive Officer

Falk Neukirch
Chief Financial Officer

RESPONSIBILITY STATEMENT

To the best of our knowledge, we assure that, in accordance with the applicable accounting principles for interim financial reporting, the interim consolidated financial statements give a true and fair view of the Group's net assets, financial position and results of operations, and that the business performance, including the business result, and the position of the Group are presented in the interim group management report in such a way that a true and fair view is given, and that the principal opportunities and risks associated with the expected development of the Group in the remaining financial year are described.

Leipzig, August 26, 2020
The Management Board of Vita 34 AG



Dr. Wolfgang Knirsch
Chief Executive Officer



Falk Neukirch
Chief Financial Officer

FINANCIAL CALENDAR

November 12, 2020

Publication of Quarterly Statement (Q3)

IMPRINT

CONTACT

Vita 34 AG
Deutscher Platz 5a
04103 Leipzig

Telephone: +49 (0)341 48792-40
Telefax: +49 (0)341 48792-39
E-mail: ir@vita34group.de

EDITORIAL TEAM

Vita 34 AG, Leipzig
Better Orange IR & HV AG, Munich


CONCEPT & DESIGN

Silvester Group, Hamburg

PUBLICATION

This interim report was published in German and English on August 27, 2020 and is available for download on our website. In case of deviations, only the German version is legally binding.

Vita 34 on the Internet: www.vita34group.de



Vita 34 AG

Registered office: Deutscher Platz 5a | 04103 Leipzig | Germany

Mailing address: Perlickstraße 5 | 04103 Leipzig | Germany

T: +49 (0)341 48792-0 | F: +49 (0)341 48792-20

ir@vita34group.de | www.vita34group.de

VITA34